Evidence map›Paper›PMID 40113912›Full record

ArticleLeukemia2025

Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice.

Chiara Rompietti, Francesco Maria Adamo, Daniele Sorcini, Filomena De Falco, Arianna Stella, Giovanni Martino, Barbara Bigerna, Erica Dorillo, Estevão Carlos Silva Barcelos, Angela Esposito and 8 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chiara Rompietti *Department of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Francesco Maria Adamo *Department of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Daniele SorciniDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Filomena De FalcoDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Arianna StellaDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Giovanni MartinoDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.ORCID 0000-0003-3957-6720
Barbara BigernaDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Erica DorilloDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Estevão Carlos Silva BarcelosDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.ORCID 0000-0001-7076-6165
Angela EspositoDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Clelia GeraciDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Roberta ArcaleniDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
Jessica BordiniIRCCS Ospedale San Raffaele, Università Vita Salute San Raffaele, Milan, Italy.
Lydia ScarfòIRCCS Ospedale San Raffaele, Università Vita Salute San Raffaele, Milan, Italy.ORCID 0000-0002-0844-0989
Emanuela RosatiDepartment of Medicine and Surgery, Biosciences and Medical Embryology Section, University of Perugia, Perugia, Italy.ORCID 0000-0002-6549-123X
Paolo GhiaIRCCS Ospedale San Raffaele, Università Vita Salute San Raffaele, Milan, Italy.ORCID 0000-0003-3750-7342
Brunangelo FaliniDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.ORCID 0000-0002-7198-5965
Paolo SportolettiDepartment of Medicine and Surgery, Institute of Hematology and Center for Hemato- Oncology Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy. paolo.sportoletti@unipg.it.ORCID 0000-0002-5630-9862

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) ID.23928Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) ID.26617Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 2018 - ID 21352Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 2024 - ID. 30768
6 · The paper itself

Abstract

Richter's transformation (RT) is an aggressive lymphoma occurring upon progression from chronic lymphocytic leukemia (CLL). Despite advances in deciphering the RT genetic architecture, the mechanisms driving this disease remain unknown. BCOR disruptive mutations were found in CLL and frequently associated with NOTCH1 aberrations, a common feature in CLL and RT. We engineered mice to knock-out Bcor in B and CLL cells of Eμ-TCL1 mice. Bcor loss resulted in alterations of the B cell compartment and favored CLL transformation into an aggressive lymphoma with reduced survival in Eμ-TCL1 mice. RNA-sequencing demonstrated a molecular signature reminiscent of human RT and implied the involvement of the T cell tumour microenvironment in the disease onset. Bcor deficiency was associated with Notch1 activation in splenic CD19 + CD5+ cells to accelerate Eμ-TCL1 mice lymphoproliferation. Notch1 inhibition progressively reduced circulating CD19+ CD5+ and RT cells infiltrating the spleen of diseased mice with concomitant reduction of PD-1 expressing T cells and improved survival. Our data demonstrated an interplay between the tumour suppressor activity of Bcor and Notch1 in RT pathogenesis with potential for tumour targeting. This model represented a new platform to uncover promising alternatives for this incurable tumour.

Indexed as

Cell Transformation, NeoplasticLeukemia, Lymphocytic, Chronic, B-CellProto-Oncogene ProteinsReceptor, Notch1Repressor ProteinsAnimalsHumansMiceMice, Inbred C57BLMice, KnockoutTumor MicroenvironmentBcor protein, mouseNotch1 protein, mouseProto-Oncogene ProteinsReceptor, Notch1Repressor Proteins

Identifiers

PMID40113912
PMCPMC12055590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.